AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 55 min read$SOLV

Solventum (NYSE:SOLV) Posts Better

Solventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.

Original reporting
financialcontent.com
Published Aug 5, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Solventum (NYSE:SOLV) Posts Better — source image
Source · financialcontent.com
Decision brief

The 30-second read

$SOLVBullishMed
01

Why it matters

Q2 beat likely drives near-term sentiment, but the forward view of flat revenue and longer-term margin pressure suggest traders should watch for evidence that transformation lifts organic growth and cash generation.

02

Market read

A company-specific earnings beat with modest growth and a flat forward revenue outlook creates a mixed setup: supportive for the stock immediately, but potentially range-bound without stronger guidance or organic acceleration.

03

What to watch

Free cash flow margin fell over five years and Q2 margin was only 6.5%, so investors may scrutinize whether transformation increases cash intensity rather than improving it.

Relevance 8/10Novelty 7/10Timing: post-results, immediately after-hours/next-session reaction

Background

The piece frames Solventum’s Q2 CY2026 results versus revenue and EPS consensus, then discusses longer-term revenue and free cash flow trends.

Company-level read

Ticker impact

$SOLVBullishMedium confidence
Context

Solventum reported Q2 CY2026 revenue of $2.21B (+2.2% YoY) and non-GAAP EPS $2.55, beating consensus estimates.

Expected impact

Likely supports a short-term bid, with follow-through dependent on whether management’s transformation improves organic growth and free cash flow margins.

Evidence & confidence

The article provides concrete Q2 results versus consensus and notes analysts expect flat revenue over the next 12 months, which can cap multiple expansion despite the beat.

Market effects

Sector

Healthcare services and solutions names may see mild sentiment spillover if investors interpret the transformation as improving earnings quality.

Regional

No specific regional catalyst beyond US healthcare earnings sentiment.

Global

Limited, as the disclosed items are company-specific financial results.

Counterpoint

What could challenge this read

Despite the beat, the article flags flat two-year revenue and expects flat revenue over the next 12 months, implying the outperformance may not translate into sustained growth.

Key entities

  • company
    Solventum

    Healthcare solutions provider reporting Q2 CY2026 results and discussing transformation, organic revenue, and free cash flow.

  • executive
    Bryan Hanson

    Solventum CEO quoted on execution and transformation progress.

Read at source← All news

Related articles

AUG 9
$SOLVMedAI 8/10

Solventum Q2 Earnings Call Highlights

Solventum (NYSE:SOLV) reported Q2 results and said normalized organic sales growth was about 4% excluding ERP timing, SKU rationalization headwinds and a partial separation benefit. MedSurg sales were $1.4B (8.9% organic), Dental $396M (15.2%), HIS $354M (5.4%). Gross margin rose to 60.1% on a $100M tariff refund; EPS was $2.55. The company is advancing a potential HIS separation and raised its 2026 outlook.

finance.yahoo.com6 min
AUG 6
$SOLVMedAI 8/10

Solventum to hive off healthcare software business, raises profit forecast

Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.

wixx.com4 min
AUG 5
$SOLVHighAI 9/10

Solventum Reports Second Quarter 2026 Financial Results

Solventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.

prnewswire.com4 min
AUG 5
$SOLVHigh

Solventum Corp (SOLV): Results of Operations and Financial Condition

Solventum Corp (SOLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results • R eported sales increased 2.2%; organic sales increased 9.5% • Announces intent to separate its Health Information Systems business segment • Increases full-year 2026 guidance for organic sales growth, adjuste

SEC EDGAR 8-K6 min
MAY 26
$SOLVMedAI 8/10

Weekly Research Analysts’ Ratings Changes for Solventum (SOLV)

Solventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).

tickerreport.com1 min
AUG 28
$DGHighAI 9/10

Dollar General gets Q2 boost from tariff refunds, delivery

Dollar General reported Q2 net income rose 33.8% to $550.3M, with sales up 5.2% to $11.3B, driven by tariff refunds and delivery growth. The company raised its full-year outlook, now expecting sales growth of 4% to 4.3% and EPS of $7.80 to $8.00. It also expanded its $1 Value Valley sections to 9,000 stores, boosting comp-store sales.

supermarketnews.com2 min